CAR-T Therapy Global Market Report 2024

The car-t therapy market size has grown rapidly in recent years. It will grow from $2.15 billion in 2023 to $2.55 billion in 2024 at a compound annual growth rate (CAGR) of 19.1%. The historical growth can be attributed to the rise in healthcare expenditure, increased pharmaceutical research and development (R&D) spending, and advancements in drug discovery.

The car-t therapy market size is expected to see rapid growth in the next few years. It will grow to $4.74 billion in 2028 at a compound annual growth rate (CAGR) of 16.7%. Forecasted growth is fueled by an increase in blood cancer incidence rates, higher healthcare expenditure, a robust drug pipeline, and a heightened focus on CAR-T therapy. Key trends include R&D investments for redesigned CAR-T therapy, developing off-the-shelf allogeneic CAR-T treatment, manufacturing next-gen CAR-T cells, utilizing AI for optimization, strategic collaborations, and acquisitions to expand CAR-T therapy portfolios.

The growth of the CAR-T therapy market is significantly influenced by increased financial support from diverse organizations aimed at fostering the development and utilization of CAR-T therapy. Governmental and non-governmental bodies extend financial aid to companies operating within the CAR-T therapy market, facilitating research and development initiatives as well as aiding patients seeking treatment for acute lymphoblastic leukemia (ALL). An illustration of such support can be observed in December 2021 when the University of California San Diego School of Medicine received a substantial funding grant of US$ 4.1 million from the California Institute for Regenerative Medicine (CIRM). This grant specifically aimed at advancing the development of innovative chimeric antigen receptor (CAR-T) cell therapy. The backing provided by various organizations toward CAR-T therapy acts as a driving force propelling the market's growth.

The escalating prevalence of cancer globally stands as a pivotal factor propelling the expansion of the CAR-T therapy market. The rising incidence of cancer signifies an increased number of diagnosed cases within specific populations or regions over defined periods. This surge in cancer prevalence has spurred extensive research endeavors and investments in cancer therapies, notably cellular immunotherapies such as CAR-T therapy. These therapies mark a significant stride in oncological advancements, addressing the critical needs of cancer patients. For instance, statistics from the American Cancer Society in 2021 projected staggering figures of new cancer cases and deaths (1.9 million new cases and 608,570 deaths) anticipated in the United States that year. Hence, the mounting prevalence of cancer serves as a primary driver propelling the growth trajectory of the CAR-T therapy market.


Companies within the CAR-T therapy market are actively engaged in clinical trials aimed at assessing the efficacy of CAR-T therapy in treating multiple myeloma, a form of cancer characterized by the accumulation of cancerous cells in the bone marrow, often encroaching upon healthy blood cells. CAR-T therapy represents a potential treatment for relapsed or refractory multiple myeloma (RRMM), with CAR-T cells engineered to target the specific cells responsible for the disease. An example of this advancement can be seen in December 2021, with Novartis unveiling T-Charge, its next-generation CAR-T platform designed as a foundational framework for various new investigational CAR-T cell therapies within the Novartis pipeline. This product was in the early clinical stage (Phase I), indicating ongoing efforts to explore its potential in treating multiple myeloma.

Major companies operating in the CAR-T cell therapies market are dedicated to innovating new products such as BioCentriq to augment their profitability within the industry. BioCentriq serves as a valuable resource for organizations involved in the realm of cell and gene therapies, facilitating advancements in development, manufacturing, and research efforts, ultimately aiming to enhance patient care. For instance, in October 2023, Terumo Blood and Cell Technologies, a Japanese medical technology company, introduced BioCentriq with the objective of generating accessible public data concerning CAR-T cell manufacturing using Terumo BCT’s CGT (Cell and Gene Therapy) manufacturing platforms. In collaboration with Terumo BCT, BioCentriq strives to pioneer publicly available data focusing on swift CAR-T cell manufacturing, employing the Quantum Flex and Finia platforms. This innovative trial aims to demonstrate the efficient production of high-quality CAR-T cells, leveraging the seamless integration of Terumo BCT's technology and BioCentriq's process expertise to establish streamlined, GMP-translatable workflows.

In July 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, successfully acquired Iveric Bio for $5.9 billion. This strategic move enhances Astellas' ability to address patients at high risk of vision loss due to ocular illnesses. The acquisition leverages Iveric Bio's expertise in ophthalmology alongside Astellas' global resources, aiming to create a leading organization in the field. The transaction was subject to standard closing requirements, including approval from Iveric Bio's stockholders and regulatory approvals. Iveric Bio is a U.S.-based biotech company.

Major companies operating in the car-t therapy market report are Gilead Sciences, Novartis AG, Biocon, Gracell Biotechnology Ltd., Aeon Therapeutics, CARsgen Therapeutics, Daiichi Sankyo, Otsuka Pharmaceutical, Ono Pharmaceutical, Japan Tissue Engineering, Nipro Corporation, Takeda Pharmaceutical Company, Astellas Pharma, Innovative Cellular Therapeutics, Cellular Biomedicine Group, PersonGen Biomedicine, Hebei Senlang Biotech, Adaptimmune(UK), Autolus Therapeutics, BioNTech, Cellectis, Celyad, Crescendo Biologics, GammaDelta Therapeutics, Immatics, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen, AstraZeneca, Bayer AG, Merck, Pfizer, Juno Therapeutics, Allogene Therapeutics, Bluebird Bio Amgen, Regen BioPharma, OncoSec Medical Incorporated, Precision BioSciences, Bellicum, Sandoz AG, GlaxoSmithKline PLC, Elekta, SudairPharma, Janssen, Aspen, Adcock Ingram.

North America was the largest region in the CAR-t therapy market in 2023. Western Europe was the second-largest region in the global CAR-T therapy market share. The regions covered in the car-t therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the car-t therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The chimeric antigen receptor -T therapy market includes revenues earned by CAR-T therapy products and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.